

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 1 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 1. Identification

GHS product identifier : Levoleucovorin Injection

Other means of identification : Not available.

Product type : Liquid.

Relevant identified uses of the substance or mixture and uses advised against

Product use : Pharmaceuticals (For intended use only.).
Observe technical data sheet/instructions for use.
Specific Treatments: Cancer.

Area of application : Professional applications.

| Uses advised against | Reason |
|-----------------------------|---------------|
| Anemia | |

Supplier's details : Meitheal Pharmaceuticals, Inc.
8700 W. Bryn Mawr, Suite 600S
Chicago, IL 60631

Telephone: 224-443-4617
www.meithealpharma.com

e-mail address of person responsible for this SDS : info@meithealpharma.com

Emergency telephone number (with hours of operation) : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

Section 2. Hazards identification

OSHA/HCS status : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

Classification of the substance or mixture : H334 RESPIRATORY SENSITIZATION - Category 1
H317 SKIN SENSITIZATION - Category 1

GHS label elements

Hazard pictograms :



Signal word : Danger

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 2 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 2. Hazards identification

| | |
|---|---|
| Hazard statements | : H317 - May cause an allergic skin reaction. H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| Precautionary statements | |
| Prevention | : P280 - Wear protective gloves. P284 - Wear respiratory protection. P261 - Avoid breathing vapor. P272 - Contaminated work clothing must not be allowed out of the workplace. |
| Response | : P304 + P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing. P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTER or doctor. P302 + P352 - IF ON SKIN: Wash with plenty of water. P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention. P363 - Wash contaminated clothing before reuse. |
| Storage | : Not applicable. |
| Disposal | : P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations. |
| Hazards not otherwise classified | : None known. |

Section 3. Composition/information on ingredients

| | |
|--------------------------------------|------------------|
| Substance/mixture | : Mixture |
| Other means of identification | : Not available. |

| Ingredient name | Other names | % | Identifiers |
|----------------------|-----------------|------|-----------------|
| Water | - | ≥90 | CAS: 7732-18-5 |
| calcium levofolinate | - | ≤3 | CAS: 80433-71-2 |
| sodium chloride | Sodium chloride | <1 | CAS: 7647-14-5 |
| sodium hydroxide | - | ≤0.1 | CAS: 1310-73-2 |

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.

Section 4. First aid measures

Description of necessary first aid measures

| | |
|--------------------|--|
| Eye contact | : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs. |
|--------------------|--|

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 3 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 4. First aid measures

- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours. In the event of any complaints or symptoms, avoid further exposure.
- Skin contact** : Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
- Ingestion** : Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

Most important symptoms/effects, acute and delayed

Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Skin contact** : May cause an allergic skin reaction.
- Ingestion** : No known significant effects or critical hazards.

Over-exposure signs/symptoms

- Eye contact** : No specific data.
- Inhalation** : Adverse symptoms may include the following:
wheezing and breathing difficulties
asthma
- Skin contact** : Adverse symptoms may include the following:
irritation
redness
- Ingestion** : No specific data.

Indication of immediate medical attention and special treatment needed, if necessary

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 4 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 4. First aid measures

- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : Do not use water jet.

Specific hazards arising from the chemical

- Hazardous thermal decomposition products** : Decomposition products may include the following materials:
carbon dioxide
carbon monoxide
nitrogen oxides
metal oxide/oxides

Special protective actions for fire-fighters

- : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters

- : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
- For emergency responders** : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 5 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 6. Accidental release measures

Environmental precautions : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

Methods and materials for containment and cleaning up

Small spill : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Large spill : Stop leak if without risk. Move containers from spill area. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

Section 7. Handling and storage

Precautions for safe handling

Protective measures : Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems or asthma, allergies or chronic or recurrent respiratory disease should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapor or mist. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.

Advice on general occupational hygiene : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

Conditions for safe storage, including any incompatibilities : Store between the following temperatures: 2 to 8°C (35.6 to 46.4°F). Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 6 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

| Ingredient name | Exposure limits |
|--|---|
| Water calcium levofolinate sodium chloride sodium hydroxide | None. None. None. ACGIH TLV (United States, 1/2024) C: 2 mg/m ³ . NIOSH REL (United States, 10/2020) CEIL: 2 mg/m ³ . OSHA PEL (United States, 5/2018) TWA 8 hours: 2 mg/m ³ . CAL OSHA PEL (United States, 5/2018) C: 2 mg/m ³ . |

Appropriate engineering controls

- : Use only with adequate ventilation. If user operations generate dust, fumes, gas, vapor or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.

Environmental exposure controls

- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures

- : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

- : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection

- : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 7 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 8. Exposure controls/personal protection

- Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

Appearance

- Physical state** : Liquid. [Clear.]
- Color** : Colorless to yellow
- Odor** : Not available.
- Odor threshold** : Not available.
- pH** : 6.5 to 8.5
- Melting point** : Not available.
- Boiling point or initial boiling point and boiling range** : Not available.
- Flash point** : Not available.
- Evaporation rate** : Not available.
- Flammability** : Not available.
- Lower and upper explosion limit/flammability limit** : Not available.

Vapor pressure

| Ingredient name | Vapor Pressure at 20°C | | | Vapor pressure at 50°C | | |
|-----------------|------------------------|-----|--------|------------------------|------|--------|
| | mm Hg | kPa | Method | mm Hg | kPa | Method |
| Water | 17.5 | 2.3 | | 92.258 | 12.3 | |

- Relative vapor density** : Not available.
- Relative density** : Not available.
- Density** : 0.977 to 1.037 g/cm³ [25°C (77°F)]
- Solubility(ies)** : Not available.
- Partition coefficient: n-octanol/water** : Not applicable.
- Auto-ignition temperature** : Not available.
- Decomposition temperature** : Not available.

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 8 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 9. Physical and chemical properties

| | |
|--|--|
| SADT | : Not available. |
| Viscosity | : Dynamic (room temperature): Not available. Kinematic (room temperature): Not available. Kinematic (40°C (104°F)): Not available. |
| Flow time (ISO 2431) | : Not available. |
| Particle characteristics | |
| Median particle size | : Not applicable. |
| Other information | |
| Physical/chemical properties comments | : No additional information. |

Section 10. Stability and reactivity

| | |
|---|---|
| Reactivity | : No specific test data related to reactivity available for this product or its ingredients. |
| Chemical stability | : The product is stable. |
| Possibility of hazardous reactions | : Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerization will not occur. |
| Conditions to avoid | : Protect from light. |
| Incompatible materials | : No specific data. |
| Hazardous decomposition products | : Under normal conditions of storage and use, hazardous decomposition products should not be produced. |

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

| Product/ingredient name | Result | Species | Dose | Exposure |
|-------------------------|-----------|---------|------------|----------|
| sodium chloride | LD50 Oral | Rat | 3000 mg/kg | - |

Irritation/Corrosion

| | | |
|---|---|-------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 9 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 11. Toxicological information

| Product/ingredient name | Result | Species | Score | Exposure | Observation |
|-------------------------|--------------------------|---------|-------|------------------|-------------|
| sodium chloride | Eyes - Moderate irritant | Rabbit | - | 10 mg | - |
| | Eyes - Moderate irritant | Rabbit | - | 24 hours 100 mg | - |
| | Skin - Mild irritant | Rabbit | - | 24 hours 500 mg | - |
| sodium hydroxide | Eyes - Mild irritant | Rabbit | - | 400 ug | - |
| | Eyes - Severe irritant | Rabbit | - | 1 % | - |
| | Eyes - Severe irritant | Rabbit | - | 0.5 minutes 1 mg | - |
| | Eyes - Severe irritant | Rabbit | - | 24 hours 50 ug | - |
| | Skin - Severe irritant | Rabbit | - | 24 hours 500 mg | - |

Sensitization

Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity

Conclusion/Summary : Not available.

Reproductive toxicity

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

| Name | Category | Route of exposure | Target organs |
|----------------------|------------|-------------------|------------------------------|
| calcium levofolinate | Category 3 | - | Respiratory tract irritation |
| sodium hydroxide | Category 3 | - | Respiratory tract irritation |

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely routes of exposure : Routes of entry anticipated: Oral, Dermal, Inhalation, Eyes.

Potential acute health effects

Eye contact : No known significant effects or critical hazards.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 10 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 11. Toxicological information

- Inhalation** : May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Skin contact** : May cause an allergic skin reaction.
- Ingestion** : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

- Eye contact** : No specific data.
- Inhalation** : Adverse symptoms may include the following:
wheezing and breathing difficulties
asthma
- Skin contact** : Adverse symptoms may include the following:
irritation
redness
- Ingestion** : No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

- Potential immediate effects** : Not available.
- Potential delayed effects** : Not available.

Long term exposure

- Potential immediate effects** : Not available.
- Potential delayed effects** : Not available.

Potential chronic health effects

- General** : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
- Carcinogenicity** : No known significant effects or critical hazards.
- Mutagenicity** : No known significant effects or critical hazards.
- Reproductive toxicity** : No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

| Product/ingredient name | Oral (mg/kg) | Dermal (mg/kg) | Inhalation (gases) (ppm) | Inhalation (vapors) (mg/l) | Inhalation (dusts and mists) (mg/l) |
|-------------------------|--------------|----------------|--------------------------|----------------------------|-------------------------------------|
| sodium chloride | 3000 | N/A | N/A | N/A | N/A |

| | | |
|--|--------------------------------------|-------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 11 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 12. Ecological information

Toxicity

| Product/ingredient name | Result | Species | Exposure |
|-------------------------|-------------------------------------|--|----------|
| sodium chloride | Acute EC50 4.74 g/L Fresh water | Algae - <i>Chlamydomonas reinhardtii</i> | 96 hours |
| | Acute EC50 519.6 mg/l Fresh water | Crustaceans - <i>Cypris subglobosa</i> | 48 hours |
| | Acute EC50 402.6 mg/l Fresh water | Daphnia - <i>Daphnia magna</i> | 48 hours |
| | Acute IC50 6.87 g/L Fresh water | Aquatic plants - <i>Lemna minor</i> | 96 hours |
| | Acute LC50 1000000 µg/l Fresh water | Fish - <i>Morone saxatilis</i> - Larvae | 96 hours |
| | Chronic LC10 781 mg/l Fresh water | Crustaceans - <i>Hyalella azteca</i> - Juvenile (Fledgling, Hatchling, Weanling) | 3 weeks |
| | Chronic NOEC 6 g/L Fresh water | Aquatic plants - <i>Lemna minor</i> | 96 hours |
| | Chronic NOEC 0.314 g/L Fresh water | Daphnia - <i>Daphnia pulex</i> | 21 days |
| | Chronic NOEC 100 mg/l Fresh water | Fish - <i>Gambusia holbrooki</i> - Adult | 8 weeks |
| sodium hydroxide | Acute EC50 40.38 mg/l Fresh water | Crustaceans - <i>Ceriodaphnia dubia</i> - Neonate | 48 hours |
| | Acute LC50 125 ppm Fresh water | Fish - <i>Gambusia affinis</i> - Adult | 96 hours |

Conclusion/Summary : Not available.

Persistence and degradability

Not available.

Bioaccumulative potential

| Product/ingredient name | LogP _{ow} | BCF | Potential |
|-------------------------|--------------------|-----|-----------|
| Water | -1.38 | - | Low |

Mobility in soil

Soil/water partition coefficient (K_{oc}) : Not available.

Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 12 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 13. Disposal considerations

cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

| | DOT Classification | IMDG | IATA |
|----------------------------|--------------------|----------------|----------------|
| UN number | Not regulated. | Not regulated. | Not regulated. |
| UN proper shipping name | - | - | - |
| Transport hazard class(es) | - | - | - |
| Packing group | - | - | - |
| Environmental hazards | No. | No. | No. |

Additional information

Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Transport in bulk according to IMO instruments : Not available.

Section 15. Regulatory information

U.S. Federal regulations : **TSCA 8(a) CDR Exempt/Partial exemption:** Not determined
United States inventory (TSCA 8b): Not determined.
Clean Water Act (CWA) 311: sodium hydroxide

Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs) : Not listed

Clean Air Act Section 602 Class I Substances : Not listed

Clean Air Act Section 602 Class II Substances : Not listed

DEA List I Chemicals (Precursor Chemicals) : Not listed



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 13 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 15. Regulatory information

DEA List II Chemicals : Not listed
(Essential Chemicals)

SARA 302/304

Composition/information on ingredients

No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312

Classification : RESPIRATORY SENSITIZATION - Category 1
SKIN SENSITIZATION - Category 1

Composition/information on ingredients

| Name | % | Classification |
|----------------------|------|--|
| calcium levofolinate | ≤3 | SKIN IRRITATION - Category 2 EYE IRRITATION - Category 2A RESPIRATORY SENSITIZATION - Category 1 SKIN SENSITIZATION - Category 1 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 |
| sodium chloride | <1 | EYE IRRITATION - Category 2A |
| sodium hydroxide | ≤0.1 | CORROSIVE TO METALS - Category 1 SKIN CORROSION - Category 1A SERIOUS EYE DAMAGE - Category 1 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 HNOC - Corrosive to digestive tract [severe] |

SARA 313

Not applicable.

State regulations

Massachusetts : None of the components are listed.

New York : None of the components are listed.

New Jersey : None of the components are listed.

Pennsylvania : None of the components are listed.

California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

| | | |
|--|--------------------------------------|-------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 14 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 15. Regulatory information

Not listed.

[Rotterdam Convention on Prior Informed Consent \(PIC\)](#)

Not listed.

[UNECE Aarhus Protocol on POPs and Heavy Metals](#)

Not listed.

Section 16. Other information

[Hazardous Material Information System \(U.S.A.\)](#)

| | | |
|------------------|---|---|
| Health | * | 2 |
| Flammability | | 0 |
| Physical hazards | | 0 |

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

[National Fire Protection Association \(U.S.A.\)](#)



[Procedure used to derive the classification](#)

| Classification | Justification |
|--|--------------------|
| RESPIRATORY SENSITIZATION - Category 1 | Calculation method |
| SKIN SENSITIZATION - Category 1 | Calculation method |

[History](#)

| | |
|--------------------------------|--------------------|
| Date of issue/Date of revision | : 12/20/2024 |
| Date of previous issue | : 01/20/2023 |
| Version | : 4.0 |
| Prepared by | : Sphera Solutions |



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

| | | |
|---|---|--------------------------------------|
| SDS Title: Levoleucovorin Injection Safety Data Sheet | SDS Number: SDS-000027 | Page Number: Page 15 of 15 |
| Function: Regulatory Affairs | Effective Date: December 20, 2024 | Version number: 4.0 |

Section 16. Other information

Key to abbreviations

- : ATE = Acute Toxicity Estimate
- AMP = Acceptable maximum peak above the acceptable ceiling concentration for an 8-hr shift
- BCF = Bioconcentration Factor
- GHS = Globally Harmonized System of Classification and Labelling of Chemicals
- IATA = International Air Transport Association
- IBC = Intermediate Bulk Container
- IMDG = International Maritime Dangerous Goods
- LogPow = logarithm of the octanol/water partition coefficient
- MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)
- N/A = Not available
- UN = United Nations

References

- : HCS (U.S.A.)- Hazard Communication Standard
- International transport regulations

Indicates information that has changed from previously issued version.

Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.